| Literature DB >> 31774722 |
Phi Luong1,2, Qian Li1,2,3, Pin-Fang Chen4, Paul J Wrighton5, Denis Chang1,2, Sean Dwyer4, Marie-Theres Bayer1,2, Scott B Snapper1,2,6, Steen H Hansen1,2, Jay R Thiagarajah1,2,6, Wolfram Goessling7,8,9, Wayne I Lencer1,2,6.
Abstract
Retrograde membrane trafficking from plasma membrane to Golgi and endoplasmic reticulum typifies one of the key sorting steps emerging from the early endosome that affects cell surface and intracellular protein dynamics underlying cell function. While some cell surface proteins and <span class="Chemical">lipids are known to sort retrograde, there are few effective methods to quantitatively measure the extent or kinetics of these events. Here we took advantage of the well-known retrograde trafficking of cholera toxin and newly defined split fluorescent protein technology to develop a quantitative, sensitive, and effectively real-time single-cell flow cytometry assay for retrograde membrane transport. The approach can be applied in high throughput to elucidate the underlying biology of membrane traffic and how endosomes adapt to the physiologic needs of different cell types and cell states.Entities:
Year: 2019 PMID: 31774722 PMCID: PMC7202069 DOI: 10.1091/mbc.E19-07-0375
Source DB: PubMed Journal: Mol Biol Cell ISSN: 1059-1524 Impact factor: 4.138
FIGURE 1:Design, development, and validation of the split-fluorescence assay for retrograde trafficking. (a) Schematic of native holotoxin CTx structure and modifications to enable split-fluorescence complementation by fusing NG2 fragment mNG211 to the N-terminus of the CTx A2-chain and reassembly with CTx B-subunit to form CTB-mNG211. (b) Pathway of retrograde trafficking for CTB-mNG211 from the plasma membrane into the Golgi and ER. (c) Retrograde trafficking to ER in K562 cells stably expressing ER-HA-mNG21-10 as assessed by flow cytometry. Representative flow cytometry graph displayed to right. Cells were treated with CTB-mNG211 for 4 h at 37°C; n = 3 independent experiments. (d) Time course of retrograde trafficking into the ER in K562 cells with 10 nM CTB-mNG211—methods are as described above; n = 2 independent experiments. Representative flow cytometry graph shows timepoints at 0, 4, and 20 h for continuous CTB-mNG211 toxin uptake and in cells treated with a 2-h toxin pulse and chase for 20 h. (e, f) Confocal microscopy of CTB-mNG211 retrograde trafficking into TGN and ER of COS7 cells stably expressing TGN or ER mNG21-10 and ER-mCherry, 6 h incubation. Cells were stained with anti-Golgin97 to mark the TGN. (g) TGN and ER retrograde trafficking in cells with 15 biological replications per condition (treated or not treated). Z-factors = 0.92 for TGN and 0.96 for ER retrograde transport. (h) Addition of tandem mNG211 to CTx improves assay sensitivity. COS7 ER-HA-mNG21-10 cells were treated with 10 nM holotoxin CT-1XmNG211 or tandem CT-2XmNG211 or CT-5XmNG211 for 3.5 h at 37°C; n = 2 independent experiments. Error bars indicate ± SEM. ****p < 0.0001 (two-tailed Student’s t test). Scale bars are 10 μm.
FIGURE 2:Quantitative measures of retrograde traffic under different conditions. (a, b) Retrograde trafficking to ER as assessed in K562 (a) and HEK293T (b) treated with the indicated compounds for 30 min before addition of CTB-mNG211. Data normalized to Mock (untreated) cells; n = 3 independent experiments, each with three biologic replicates, and mean marked as one point for each condition. (c) Retrograde trafficking to TGN performed as in a; n = 3 independent experiments (BFA 10 µM). (d) Retrograde trafficking to ER in cells pretreated with DTT (4 mM) or tunicamycin (5 μg/ml); n = 3 independent experiments. (e) COS7 cells stably expressing ER-mCherry and ATLASTIN-K80A, CLIMP63, or DP1. (f) Retrograde trafficking to ER in cells overexpressing CLIMP63, DP1, or ATLASTIN1-K80A. Data normalized by CTB-Alexa Fluor 488 uptake; n = 5 independent experiments. (g) Retrograde trafficking to TGN as in f; n = 4 independent experiments. (h) Western blot for HA-epitope in HEK293T cells stably transfected with empty vector (EV), HA-tagged ATLASTIN-K80A, CLIMP63 or DP1, and HA-tagged TGN-mNG21-10. Mean ± SEM, ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (two-tailed Student’s t test). Scale bars are 10 μm.
FIGURE 3:Retrograde trafficking in monogenic human disease. (a) Knockdown of MYOVB and TTC7a using two unique shRNAs in HEK293T cells stably expressing TGN-HA-mNG21-10 enhances retrograde trafficking to TGN. Data normalized to control shRNA at 20 nM CTB-mNG211/CTB Alexa Fluor 488 loading; n = 4 independent experiments. (b, c) Representative flow cytometry graphs from a. (d) Retrograde trafficking to ER as in a. n = 3 independent experiments. (e) Retrograde trafficking to TGN in human iPSCs stably expressing TGN-HA-mNG21-10 and treated or not with 2 μM GM1 C12:0. Error bars indicate ± SEM, ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001 (two-tailed Student’s t test).